At the Forefront of
Cell and Gene Therapy
Next-generation cell and gene therapies (CGTs) are our specialty. Our directive of collaborative partnership converges with deep industry experience and innovation using the latest technologies to drive the future of cell and gene therapy manufacturing.
What Defines Us
To manufacture a disease-free world
By prioritizing client partnerships and CGT manufacturing innovation, together we will improve the lives of patients around the world
A Future-fit Foundation: Our History of Innovation
Years of CGT Scientific and Manufacturing Expertise
OmniaBio is more than a CDMO. We are a crucial component of a broader, well-established CGT ecosystem. A subsidiary of CCRM, OmniaBio leverages key expertise and infrastructure to offer clients best in class end-to-end capabilities in cell and gene therapy.
When you work with OmniaBio, you leverage a collaborative partnership to accelerate your CGT product to the next phase of development. As part of a larger CGT ecosystem, OmniaBio embraces an innovative culture that fosters deep expertise and novel analytical and manufacturing technologies to catalyze the development process.
Join Our Team
Are you passionate about cell and gene therapy? Do you embrace novel technologies that have the potential to change the industry? Join OmniaBio in delivering the future of cell and gene therapy today.
Stay up-to-date with all the cell and gene therapy insights and trends.
Our Expertise on Demand
Related Thought Leadership & Resources
Expertise in process development and manufacturing under one roof in state-of-the-art facilities.
Meet the leadership team of OmniaBio.
Join a great team of talented, passionate people advancing cell and gene therapies.
See OmniaBio in action with our case studies.
Expert insights into CGT manufacturing, brought to you by OmniaBio.